Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1111/dom.12055. Epub 2013 Jan 24.
Affiliations
- PMID: 23279373
- DOI: 10.1111/dom.12055
Randomized Controlled Trial
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial
M Takihata et al. Diabetes Obes Metab. 2013 May.
Abstract
Aims: To compare the efficacy and safety of these two agents and the impact on surrogate markers related to diabetic complications in Japanese type 2 diabetic patients.
Methods: In a multicenter, open-label trial, 130 patients whose diabetes had been inadequately controlled (HbA1c, 6.9-9.5%) with metformin and/or sulphonylurea were randomly assigned to a sitagliptin group (50 mg/day) or a pioglitazone group (15 mg/day) and were followed up for 24 weeks. At 16 weeks, if the patient's HbA1c level was ≥6.5%, the dose of sitagliptin or pioglitazone was increased up to 100 or 30 mg/day, respectively. Main outcome measure was the difference in the mean changes in the HbA1c level from baseline at 24 weeks between these two groups.
Results: Of the 130 patients who were enrolled, 115 subjects (sitagliptin group: 58 patients, pioglitazone group: 57 patients) completed this trial. At 0 weeks, the mean HbA1c level was 7.47 ± 0.66% in the sitagliptin group and 7.40 ± 0.61% in the pioglitazone group. At 24 weeks, the mean changes in the HbA1c level from baseline were -0.86 ± 0.63% versus -0.58 ± 0.68% (p = 0.024). Hypoglycaemia (2 patients, 3.4% vs. 2 patients, 3.5%), gastrointestinal symptoms (3 patients, 5.2% vs. 1 patient, 1.8%) and pretibial oedema (0 patients, 0% vs. 39 patients, 68.4%, p < 0.001) were observed for 24 weeks.
Conclusions: Sitagliptin was not only more tolerable, but also more effective than pioglitazone in Japanese type 2 diabetic patients who had been treated with metformin and/or sulphonylurea.
© 2012 Blackwell Publishing Ltd.
Similar articles
- Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
Liu SC, Chien KL, Wang CH, Chen WC, Leung CH. Liu SC, et al. Endocr Pract. 2013 Nov-Dec;19(6):980-8. doi: 10.4158/EP13148.OR. Endocr Pract. 2013. PMID: 23807528 Clinical Trial. - Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ. Yoon KH, et al. Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17. Diabetes Obes Metab. 2012. PMID: 22405352 Clinical Trial. - One-year real-life efficacy of sitagliptin revealed importance of concomitant pioglitazone use in Japanese patients with type 2 diabetes mellitus.
Suzuki A, Yoshimura N, Mashimo Y, Numakura M, Fujimaki Y, Maeda T, Ishikawa T, Fujimori S, Eto K. Suzuki A, et al. Diabetes Metab Syndr. 2013 Jul-Sep;7(3):143-7. doi: 10.1016/j.dsx.2013.06.009. Epub 2013 Jul 20. Diabetes Metab Syndr. 2013. PMID: 23953179 - Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N. Mikhail N. Vasc Health Risk Manag. 2008;4(6):1221-7. doi: 10.2147/vhrm.s3374. Vasc Health Risk Manag. 2008. PMID: 19337535 Free PMC article. Review. - Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ, Moniri NH, Smiley DD. Ryan GJ, et al. Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Am J Health Syst Pharm. 2013. PMID: 23784159 Review.
Cited by
- Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Gong Y, Bai X, Zhang D, Yang X, Qin Z, Yang Y, Zhou Y, Meng J, Liu X. Gong Y, et al. Lipids Health Dis. 2024 May 25;23(1):157. doi: 10.1186/s12944-024-02132-x. Lipids Health Dis. 2024. PMID: 38796440 Free PMC article. - An Attempt to Replicate Randomized Trials of Diabetes Treatments Using a Japanese Administrative Claims and Health Checkup Database: A Feasibility Study.
Wakabayashi R, Hirano T, Koga T, Kuwatsuru R. Wakabayashi R, et al. Drugs Real World Outcomes. 2023 Jun;10(2):235-247. doi: 10.1007/s40801-023-00353-7. Epub 2023 Feb 1. Drugs Real World Outcomes. 2023. PMID: 36725811 Free PMC article. - Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Wang Q, Ma L, Zhang Y, Zhang L, An Y, Liu J, Wang G. Wang Q, et al. Diabetes Ther. 2021 Apr;12(4):1029-1039. doi: 10.1007/s13300-021-01023-z. Epub 2021 Feb 24. Diabetes Ther. 2021. PMID: 33625721 Free PMC article. - Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis.
Takahashi M, Shibasaki M, Echizen H, Kushiyama A. Takahashi M, et al. PLoS One. 2020 Jul 24;15(7):e0236603. doi: 10.1371/journal.pone.0236603. eCollection 2020. PLoS One. 2020. PMID: 32706828 Free PMC article. - Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
Iijima T, Aoki K, Kondo Y, Terauchi Y. Iijima T, et al. J Clin Med Res. 2020 Feb;12(2):73-78. doi: 10.14740/jocmr4084. Epub 2020 Feb 1. J Clin Med Res. 2020. PMID: 32095176 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical